Lab Results

What Is an Optimal IGF-1 Level?

Most labs flag IGF-1 as 'normal' across a wide age-adjusted range, but research suggests the sweet spot for longevity and metabolic health is narrower than that. Understanding what your IGF-1 number actually means — and what moves it — can change how you approach recovery, body composition, and healthy aging.

Jared Murray ·Co-Founder & Head of Health Research, Ones · ·10 min read
IGF-1lab resultsbiomarkersgrowth hormonelongevityoptimal ranges
What Is an Optimal IGF-1 Level?

What Is an Optimal IGF-1 Level?

For most healthy adults, an optimal IGF-1 level sits in the upper-middle of the age-adjusted reference range — roughly 150–250 ng/mL for adults aged 30–60 — not simply "within normal limits." The main caveat: optimal IGF-1 is highly context-dependent. Very high levels (above 300 ng/mL in adults) are linked to increased cancer risk in epidemiological data, while very low levels (below 100 ng/mL) associate with poor muscle maintenance, metabolic dysfunction, and cardiovascular risk. Athletes, people recovering from illness, and older adults each have different targets.

---

What Does IGF-1 Actually Do?

Insulin-like growth factor 1 (IGF-1) is a peptide hormone produced primarily in the liver in response to growth hormone (GH) signaling. It mediates most of GH's anabolic effects — stimulating cell growth, protein synthesis, and tissue repair across nearly every organ system.

Beyond muscle, IGF-1 plays a central role in:

  • Bone density: IGF-1 activates osteoblasts and is a key driver of peak bone mass in adolescence and maintenance in adulthood (Boonen et al., JCEM 1999; PMID: 10022403).
  • Cognitive function: IGF-1 receptors are dense in the hippocampus and prefrontal cortex; low levels correlate with accelerated cognitive decline in aging populations.
  • Insulin sensitivity: IGF-1 shares structural similarity with insulin and exerts modest insulin-like metabolic effects, reducing fasting glucose and improving glucose uptake in skeletal muscle.
  • Cellular repair and autophagy: Here is where the nuance begins. IGF-1 signaling via the PI3K/Akt/mTOR pathway suppresses autophagy — the cellular self-cleaning process associated with longevity. This is why some longevity researchers view chronically elevated IGF-1 as a double-edged sword.

Understanding this dual role — anabolic and growth-promoting on one hand, potentially pro-aging on the other — is essential to interpreting your personal number. As with many biomarkers, context and trajectory matter more than a single snapshot. For comparison, reviewing how standard lab reference ranges differ from optimal ranges provides useful framing.

---

IGF-1 Reference Ranges vs. Optimal Ranges

Most clinical laboratories report IGF-1 using broad, age-adjusted reference intervals. Here's what those ranges typically look like, alongside narrower "functional optimal" zones supported by the research literature:

Age GroupTypical Lab Reference Range (ng/mL)Functional Optimal (ng/mL)Notes
20–30115–355200–300Peak anabolic years; higher end acceptable
31–45100–310170–260Gradual decline expected; aim for upper-middle
46–6085–275150–240Below 120 warrants investigation
61–7575–235120–200Low end links to sarcopenia risk
75+60–190100–170Quality of life and functional outcomes prioritized

These "functional optimal" zones are derived from population studies linking mid-to-upper-normal IGF-1 to lower all-cause mortality (Renehan et al., Lancet 2004; PMID: 15016485), better musculoskeletal function, and favorable metabolic profiles — without the cancer-associated signal seen at the high extreme.

Lab ranges alone can be misleading. Someone at 90 ng/mL might be flagged "normal" for their age bracket but still experience low IGF-1 symptoms like fatigue, poor recovery, and declining lean mass. As with optimal fasting insulin levels, the reference range is a population floor, not a performance ceiling.

---

What Causes IGF-1 to Go Out of Range?

If you've received an unexpected result, the causes of IGF-1 being out of range are worth reviewing in detail. For this article, here is a structured summary:

Low IGF-1 (below functional optimal) is associated with:

  1. Growth hormone deficiency (pituitary dysfunction)
  2. Liver disease or reduced hepatic IGF-1 synthesis capacity
  3. Protein malnutrition or very low-calorie dieting
  4. Chronic systemic inflammation (CRP elevation suppresses GH signaling)
  5. Hypothyroidism — thyroid hormone is required for GH receptor expression
  6. Aging-related somatopause (physiological GH decline after age 30)
  7. Insulin resistance paradox: some individuals with hyperinsulinemia show low IGF-1 despite high GH, due to hepatic GH resistance

High IGF-1 (above functional optimal or above lab upper limit) is associated with:

  1. Acromegaly (pathological GH excess from a pituitary adenoma)
  2. Exogenous GH administration
  3. High protein intake combined with significant resistance training
  4. Certain cancers (some tumors produce IGF-1 locally)
  5. Obesity paradox: central adiposity can transiently raise IGF-1 through insulin-driven GH secretion

Chronic inflammation is a consistent thread running through low-IGF-1 presentations. Elevated CRP and interleukin-6 impair GH receptor sensitivity in the liver, suppressing IGF-1 output even when GH pulses are adequate. This is one reason optimal CRP levels are worth monitoring alongside IGF-1.

---

IGF-1 and Longevity: The Paradox

The longevity data on IGF-1 is genuinely complex, and you'll encounter conflicting claims in the supplement and biohacking space. Here's an honest summary.

Lower IGF-1 in animal models: In C. elegans, Drosophila, and rodents, reduced insulin/IGF-1 signaling (IIS pathway) consistently extends lifespan — sometimes dramatically. Caloric restriction lowers IGF-1 and extends rodent lifespan. These findings sparked hypotheses that lower IGF-1 is better for human longevity too.

Human epidemiology tells a more nuanced story: A large meta-analysis of prospective studies found that IGF-1 follows a U-shaped association with mortality in humans. Both the lowest quartile (below ~100 ng/mL) and the highest quartile (above ~300 ng/mL in older adults) are associated with higher all-cause mortality compared to the middle (Burgers et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21715540).

Cancer epidemiology: Elevated circulating IGF-1 is associated with modestly increased risk of premenopausal breast cancer, colorectal cancer, and prostate cancer in large cohort data (Key et al., Lancet Oncology 2010; PMID: 20493771). However, the absolute risk increase is small at levels within the upper-normal lab range — most of the signal comes from pathological elevations.

The practical takeaway: For healthy adults, the goal is not to minimize IGF-1, but to maintain it in the functional optimal band. Chasing very low IGF-1 through aggressive caloric restriction trades muscle mass, bone density, and cognitive function for a longevity hypothesis that is not robustly established in humans.

---

IGF-1 Replacement Therapy

IGF-1 replacement therapy — using recombinant human IGF-1 (mecasermin, sold as Increlex) — is an FDA-approved treatment for children with severe primary IGF-1 deficiency (Laron syndrome) due to GH receptor insensitivity. Its use in adults is more limited and largely investigational or off-label.

Approved and evidence-backed uses:

  • Severe IGF-1 deficiency in children: mecasermin at 0.04–0.12 mg/kg/dose twice daily has demonstrated significant improvements in height velocity and metabolic markers (Chernausek et al., JCEM 2007; PMID: 17405840).
  • ALS (amyotrophic lateral sclerosis): early trials showed modest benefit in slowing functional decline; subsequent larger trials produced mixed results.
  • Insulin resistance in patients with leprechaunism and Rabson-Mendenhall syndrome: IGF-1 replacement has demonstrated glucose-lowering effects in these rare conditions.

What about adults with low-normal IGF-1?

This is where most people's questions arise. Direct IGF-1 therapy for "age-related" low levels is not standard of care and carries significant risks: hypoglycemia (IGF-1 lowers blood sugar), fluid retention, jaw/hand growth, and theoretical cancer promotion with long-term use.

Most clinicians working in functional and longevity medicine address low-normal IGF-1 by targeting upstream drivers: optimizing GH pulse amplitude through sleep quality, resistance training, adequate dietary protein, and treating any underlying thyroid or inflammatory conditions — rather than administering IGF-1 or GH directly.

---

Natural Strategies That Influence IGF-1

Several lifestyle and nutritional variables have demonstrated meaningful effects on circulating IGF-1 in controlled trials:

1. Resistance training: Progressive resistance exercise acutely raises GH, which drives IGF-1 synthesis. A 16-week resistance training program in older adults raised IGF-1 by approximately 20% compared to sedentary controls.

2. Dietary protein: IGF-1 is exquisitely sensitive to protein intake. Vegan diets typically produce 13% lower IGF-1 than omnivore diets in cohort data, largely due to lower protein and leucine availability. Adequate intake (1.2–1.6 g/kg/day) supports hepatic IGF-1 output.

3. Sleep quality: The majority of GH secretion occurs during slow-wave sleep (SWS). Poor sleep — fewer than 6 hours or fragmented sleep architecture — measurably blunts GH pulsatility and downstream IGF-1.

4. Zinc adequacy: Zinc is a cofactor for GH receptor signaling. Zinc deficiency suppresses both GH and IGF-1 — a well-characterized relationship in pediatric nutrition literature (Hambidge, AJCN 2000; PMID: 10919955). Repleting zinc in deficient adults can modestly raise IGF-1 within weeks.

5. Managing chronic inflammation: As noted above, elevated CRP and IL-6 blunt hepatic GH receptor expression. Reducing inflammatory load — through omega-3 fatty acids, anti-inflammatory diet patterns, and addressing root causes — can improve GH sensitivity and support IGF-1 recovery.

---

What This Means for Your Formula

Ones analyzes biomarkers including IGF-1, alongside inflammatory markers like CRP, thyroid function, and metabolic indicators, to identify the upstream drivers most likely suppressing or elevating your levels. The platform then builds a personalized capsule formula targeting those mechanisms — not IGF-1 directly, but the physiological environment that governs it.

For individuals presenting with low-normal IGF-1 alongside elevated inflammatory markers and suboptimal zinc status, a Ones formula might include:

  • Zinc (as zinc bisglycinate, 15–25 mg): Supporting GH receptor signaling and IGF-1 synthesis. The dose aligns with the repletion range used in deficiency correction trials, not arbitrary supplementation.
  • Omega-3 (EPA/DHA at clinical doses): EPA and DHA reduce IL-6 and TNF-α, addressing the inflammatory suppression of hepatic GH sensitivity. Ones sources pharmaceutical-grade EPA/DHA dosed to the ranges used in intervention trials.
  • Liver Support (Ones proprietary System Blend): The liver is the primary site of IGF-1 synthesis. Ones' Liver Support blend is formulated to support hepatic function and reduce oxidative stress in hepatocytes — relevant when low IGF-1 traces back to reduced hepatic output rather than GH deficiency.

If your IGF-1 is running high alongside other metabolic signals, the formula emphasis shifts entirely — toward inflammation resolution, blood sugar regulation, and ingredients that support insulin sensitivity rather than those that might further stimulate anabolic signaling.

This is the core difference between a personalized formula and a generic stack: the same biomarker reading doesn't always call for the same response.

---

Key Takeaways

  • "Normal" and "optimal" IGF-1 are not the same thing. A result within the lab reference range can still be functionally low, particularly for adults in the lower quartile of their age bracket.
  • The functional optimal for most adults is roughly 150–250 ng/mL, sitting in the upper-middle of age-adjusted ranges — high enough to support muscle, bone, and cognition, without reaching the elevated zone linked to cancer epidemiology.
  • IGF-1 follows a U-shaped mortality curve in humans. Both very low and very high levels are associated with worse outcomes; the longevity goal is optimization, not minimization.
  • Low IGF-1 most commonly traces back to poor sleep, protein insufficiency, chronic inflammation, zinc inadequacy, or thyroid dysfunction — all of which are modifiable.
  • IGF-1 replacement therapy (mecasermin) is FDA-approved only for severe deficiency in children; adult off-label use carries meaningful risks and is not standard of care.
  • Upstream interventions — sleep quality, resistance training, protein intake, anti-inflammatory nutrition, and correcting micronutrient gaps — are the first-line approach to supporting healthy IGF-1 in adults without pathological GH deficiency.

---

Always consult a qualified healthcare provider before making changes to your supplement regimen or interpreting lab results for clinical decisions. IGF-1 results should be interpreted in the context of your full clinical picture, including GH stimulation testing where indicated.

Written by Jared Murray, Co-Founder & Head of Health Research, Ones.

Jared is the co-founder and head of health research at Ones, with 25 years applying nutrition science, biomarker interpretation, and clinical supplementation research to individual health programs. He leads the editorial process for the Ones Health Library, where lab data, wearable biometrics, and peer-reviewed clinical research are translated into evidence-based, personalized supplement guidance.

Disclosure: Ones formulates and sells personalized supplements that may include ingredients discussed in this article. We have a financial interest in the products mentioned. Recommendations are based on published research and our editorial standards, not sales targets.

This article is educational content, not medical advice. Consult a healthcare provider before changing your supplement regimen.

Further reading

Related reading